Dermorphin
Potent opioid-like peptide originally isolated from amphibian skin, occasionally discussed in experimental analgesia and performance contexts.
This page is for general educational and informational purposes only. It is not medical advice and does not replace professional medical judgment. Always consult a qualified clinician before starting, stopping, or changing any medication or protocol.
Overview
Dermorphin is a potent opioid-like peptide originally isolated from amphibian skin secretions. It has been studied primarily as a research tool and has appeared in discussions about experimental analgesia and performance enhancement.
Mechanism of action
Dermorphin exhibits high affinity for certain opioid receptors, leading to strong analgesic effects in animal models.
Indications and use context
Dermorphin is not an approved human medicine in most jurisdictions. Reports of non-regulated use, including in animal sports, have raised significant safety and regulatory concerns.
Safety and side effects
As with other potent opioids, risks may include respiratory depression, sedation, dependence, and misuse.
Lack of standardized formulations and dosing further complicates safety assessment outside research settings.
Pharmacology and dosing considerations
Dermorphin is a potent mu-opioid agonist, estimated to be 30–40 times more potent than morphine.
There is no established safe dosing protocol for humans in a research or wellness context.
Risks:- Severe respiratory depression.
- High potential for overdose and death at microgram-level doses.
- Rapid development of tolerance and dependence.
Any use outside of strictly controlled veterinary or laboratory settings is considered extremely dangerous.
Formulations and combinations
When listed in catalogs, dermorphin may appear as a research peptide. Its use in combination with other agents, particularly other CNS depressants, can increase risk.
Research and evidence snapshot
Research has focused on analgesic potency and receptor pharmacology, mainly in preclinical models. There is little high-quality clinical evidence for therapeutic use.
Frequently asked questions
Future FAQs may address how dermorphin compares conceptually with approved opioid medications and why regulatory frameworks treat non-approved opioids with particular caution. Answers will remain educational and non-prescriptive.
Sport & Anti-Doping Warning
Dermorphin became notorious in horse racing as a potent opioid peptide (sometimes dubbed 'frog juice') illegally administered to racehorses to dull pain and enhance performance.
- >Equine industry discussion of dermorphin positives and zero-tolerance policies
- >Anti-doping guidance on narcotic analgesics and related peptides in competition
While most famous in veterinary sport, dermorphin and similar non-approved opioids would also be treated as prohibited narcotics in human athletics.
Comments
Loading comments...
Get the Standard Protocols.
Join 12,000+ researchers. Receive weekly breakdowns of new compounds, safety data updates, and source verification reports.